🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. TQJ230, INCLISIRAN, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  2. TQJ230, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Apheresis

    phase 3 small molecule active

    1 trial

  3. TRUQAP 160 mg film-coated tablets, Fulvestrant Dr. Reddy’s 250 mg Solution For Injection in Pre-Filled Syringe, RLY-2608, Fulvestrant EVER Pharma 250 mg solution for injection in pre-filled syringe, Fulvestrant Dr. Reddys 250 mg solución inyectable en jeringa precargada EFG, TRUQAP 200 mg film-coated tablets

    Relay Therapeutics

    PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  4. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Kidney Transplant Rejection

    phase 3 small molecule active

    1 trial

  5. Tablet placebo for aficamten 5mg tablet, Aficamten

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  6. Taldefgrobep, Placebo Solution for injection in pre-filled syringe, Taldefgrobep

    Lacuna Pharma Pty Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  7. Tamiflu 75 mg hard capsules, DOLIPRANE 1000 mg, poudre pour solution buvable en sachet-dose

    Pari Pharma GmbH

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  8. Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution

    AXIM BIOTECHNOLOGIES, INC.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  9. Tebipenem pivoxil, SODIUM CHLORIDE, IMIPENEM AND CILASTATIN , Placebo to match Tebipenem pivoxil, tablet

    Spero Therapeutics

    complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  10. Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Cancer (Future parent protocols may include other cancer that are not included in this section)

    phase 3 small molecule active

    1 trial

  11. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.

    phase 3 small molecule active

    1 trial

  12. Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo

    Hoffmann-La Roche

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  13. Tedizolid (BAY119-2631)

    Bayer HealthCare AG

    Bacterial Infections

    phase 3 small molecule completed

    1 trial

  14. Telavancin

    CUMBERLAND PHARMACEUTICALS INC

    Staphylococcal Skin Infection

    phase 3 small molecule completed

    2 trials

  15. Testosterone Gel 1%, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Bomba de gel transparente, donde la sustancia activa (testosterona) fue sustituida por agua purificada.

    The George Institute

    low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

    phase 3 small molecule active

    1 trial

  16. Testosterone Transdermal System

    Warner Chilcott Deutschland GmbH

    Hypoactive Sexual Desire Disorder

    phase 3 small molecule completed

    1 trial

  17. Tetronine

    Cardiff Oncology

    Postoperative; Dysfunction Following Cardiac Surgery

    phase 3 small molecule completed

    1 trial

  18. Tezepelumab

    AstraZeneca

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 mab active

    2 trials

  19. Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  20. Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  21. Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Chronic Rhinosinusitis with Nasal Polyposis

    phase 3 small molecule active

    1 trial

  22. Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Severe Asthma

    phase 3 small molecule active

    1 trial

  23. Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo

    AstraZeneca AB

    Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus

    phase 3 small molecule active

    1 trial

  24. The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study

    GlaxoSmithKline

    Asthma with type 2 inflammation characterized by an eosinophilic phenotype

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources